Coordinated expression of cyclin D1 and LEF-1/TCF transcription factor is restricted to a subset of hepatocellular carcinoma

Liver International

Volumn 25, Issue 4, 2005, Pages 839-847

  Schmitt Graeff, Annette ^a   Ertelt Heitzmann, Viktoria ^a   Allgaier, Hans Peter ^a,d   Olschewski, Manfred ^a   Nitschke, Roland ^a   Haxelmans, Sabine ^a   Koelble, Konrad ^b   Behrens, Jürgen ^c   Blum, Hubert Erich ^a  

^a UNIVERSITY OF FREIBURG   (Germany)

^b HUMBOLDT UNIVERSITY   (Germany)

^c UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

^d Helios Klinik Titisee Neustadt   (Germany)

Author keywords

catenin; Cyclin D1; Hepatocarcinogenesis; LEF 1 TCF factor; Wnt pathway

Indexed keywords

BETA CATENIN; CYCLIN D1; KI 67 ANTIGEN; LYMPHOID ENHANCER FACTOR 1; T LYMPHOCYTE FACTOR; TRANSCRIPTION FACTOR; UNCLASSIFIED DRUG; WNT PROTEIN;

ADOLESCENT; ADULT; AGED; ARTICLE; CANCER GRADING; CANCER STAGING; CANCER SURVIVAL; CELLULAR DISTRIBUTION; CHILD; CONFOCAL LASER MICROSCOPY; CONTROLLED STUDY; CORRELATION ANALYSIS; DOWN REGULATION; FEMALE; GENE TARGETING; HUMAN; HUMAN TISSUE; IMMUNOFLUORESCENCE; IMMUNOHISTOCHEMISTRY; LIVER BIOPSY; LIVER CELL CARCINOMA; MAJOR CLINICAL STUDY; MALE; PATHOGENESIS; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; QUANTITATIVE ANALYSIS; TUMOR VOLUME;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; BETA CATENIN; CARCINOMA, HEPATOCELLULAR; CELL NUCLEUS; CHILD; CYCLIN D1; CYTOSKELETAL PROTEINS; DNA-BINDING PROTEINS; FEMALE; FLUORESCENT ANTIBODY TECHNIQUE; HUMANS; IMAGE PROCESSING, COMPUTER-ASSISTED; IMMUNOHISTOCHEMISTRY; KI-67 ANTIGEN; LIVER NEOPLASMS; LYMPHOID ENHANCER-BINDING FACTOR 1; MALE; MICROSCOPY, CONFOCAL; MIDDLE AGED; SURVIVAL RATE; TRANS-ACTIVATORS; TRANSCRIPTION FACTORS; TUMOR MARKERS, BIOLOGICAL;

EID: 22844451906     PISSN: 14783223     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1478-3231.2005.01069.x     Document Type: Article

References (42)

1. Cadigan K M, Nusse R. Wnt signaling: a common theme in animal development. Genes Dev 1997; 11: 3286-305.
2. Polakis P. Wnt signaling and cancer. Genes Dev 2000; 14: 1837-51.
3. Behrens J, Jerchow B A, Wurtele M, et al. Functional interaction of an axin homolog, conductin, with beta-catenin, APC, and GSK3beta. Science 1998; 280: 596-9.
4. Eastman Q, Grosschedl R. Regulation of LEF-1/TCF transcription factors by Wnt and other signals. Curr Opin Cell Biol 1999; 11: 233-40.
5. Grotewohl L, Rüther U. The Wnt antagonist Dickkopf -1 is regulated by Bmp signaling and c-Jun and modulates programmed cell death. EMBO J 2002; 21: 966-75.
6. Behrens J. Cadherins and catenins: role in signal transduction and tumor progression. Cancer Metastasis Rev 1999; 18: 15-30.
7. Giles R H, van Es J H, Clevers H. Caught up in a Wnt storm: Wnt signaling in cancer. Biochim Biophys Acta 2003; 1653: 1-24.
8. Kolligs F T, Bommer G, Göke B. Wnt/beta-catenin/Tcf signaling: a critical pathway in gastrointestinal tumorigenesis. Digestion 2002; 66: 131-44.
9. Wei Y u, van Nhieu J T, Prigent S, et al. Altered expression of E-cadherin in hepatocellular carcinoma: correlations with genetic alterations, β-catenin expression, and clinical features. Hepatology 2002; 36: 692-701.
10. Satoh S, Daigo Y, Furukawa Y, et al. AXIN1 mutations in hepatocellular carcinomas, and growth suppression in cancer cells by virus-mediated transfer of AXIN1. Nat Genet 2000; 24: 245-50.
11. Roose J, Clevers H. TCF transcription factors: molecular switches in carcinogenesis. Biochem Biophys Acta 1999; 1424(2-3): M23-37.
12. Behrens J, von Kries J P, Kühl M, et al. Functional interaction of β-catenin with the transcription factor LEF-1. Nature 1996; 382: 638-42.
13. Hovanes K, Li T W, Munguia J E, Truong T, et al. Beta-catenin-sensitive isoforms of lymphoid enhancer factor-1 are selectively expressed in colon cancer. Nat Genet 2001; 28: 53-7.
14. Shtutman M, Zhurinsky J, Simcha I, et al. The cyclin D1 gene is a target of the beta-catenin/Lef-1 pathway. Proc Natl Acad Sci USA 1999; 96: 5522-7.
15. Tetsu O, McCormick F. Beta-catenin regulates expression of cyclin D1 in colon carcinoma cells. Nature 1999; 398: 422-6.
16. He T C, Sparks A B, Rago C, et al. Identification of c-myc as a target of the APC pathway. Science 1998; 281: 1438-41.
17. Kolligs F T, Nieman M T, Winer I, et al. ITF-2, a downstream target of the Wnt/TCF pathway, is activated in human cancers with beta-catenin defects and promotes neoplastic transformation. Cancer Cell 2002; 1: 145-55.
18. Cardoret A, Ovejero C, Terris B, et al. New targets of beta-catenin signaling in the liver are involved in the glutamine metabolism. Oncogene 2002; 21: 8293-301.
19. Crawford H C, Fingleton B, Gustavson M D, et al. The PEA3 subfamily of Ets transcription factors synergizes with beta-catenin-LEF-1 to activate matrylisin transcription in intestinal tumors. Mol Cell Biol 2001; 21: 1370-83.
20. Aoki M, Sobek V, Maslyar D J, et al. Oncogenic transformation by beta-catenin: deletion analysis and characterization of selected target genes. Oncogene 2002; 21: 6983-91.
21. Lévy L, Neuvet C, Renard C A, et al. Transcriptional activation of interleukin-8 by beta-catenin-Tcf4. J Biol Chem 2002; 277: 42386-93.
22. Ovejero C, Cavard C, Périanin A, et al. Identification of the leukocyte cell-derived chemotaxin 2 as a direct target gene of β-catenin in the liver. Hepatology 2004; 40: 167-76.
23. Deane N G, Parker M A, Aramandla R, et al. Hepatocellular carcinoma results from chronic cyclin D1 overexpression in transgenic mice. Cancer Res 2003; 61: 5389-95.
24. Gotoh J, Obata M, Yoshie M, et al. Cyclin D1 overexpression correlates with β-catenin activation, but not with H-ras mutations, and phosphorylation of Akt, GSKβ and ERK1/2 in mouse hepatic carcinogenesis. Carcinogenesis 2003; 24: 435-42.
25. Joo M, Lee H K, Kang Y K. Expression of beta-catenin in hepatocellular carcinoma in relation to tumor cell proliferation and cyclin D1 expression. J Korean Med Sci 2003; 18: 211-7.
26. Prange W, Breuhahn K, Fischer F, et al. Beta-catenin accumulation in the progression of human hepatocarcinogenesis correlates with loss of E-cadherin and accumulation of p53, but not with expression of conventional WNT-1 target genes. J Pathol 2003; 201: 250-9.
27. Cui J, Zhou X, Liu Y, et al. Wnt signaling in hepatocellular carcinoma: analysis of mutation and expression of beta-catenin and TCF-4 and glycogen synthase kinase 3-beta genes. J Gastroenterol Hepatol 2003; 18: 280-7.
28. Schmitt-Gräff A, Ertelt V, Allgaier H P, et al. Cellular retinol-binding protein-1 in hepatocellular carcinoma correlates with β-catenin, Ki-67 index and patient survival. Hepatology 2003; 38: 470-80.
29. Hirohashi S, Ishak K G, Kojiro M, et al. Hepatocellular carcinoma. In: Hamilton S R, Aaltonen L A, eds. World Health Classification of Tumors. Pathology and Genetics of Tumors of the Digestive System. Lyon: IARC Press, 2000; 159-72.
30. Okuda K, Ohtsuki T, Obata H, et al. Natural history of hepatocellular carcinoma and prognosis in relation to treatment. Study of 850 patients. Cancer 1985; 56: 918-28.
31. Peng S Y, Chou S P, Hsu H C. Association of downregulation of cyclin D1 and overexpression of cyclin E with p53 mutation, high tumor grade and poor prognosis in hepatocellular carcinoma. J Hepatol 1998; 29: 281-9.
32. Azechi H, Nishida N, Fukuda Y, et al. Disruption of the p16/cyclin D1/retinoblastoma protein pathway in the majority of human hepatocellular carcinomas. Oncology 2001; 60: 346-54.
33. Nishida N, Fukuda Y, Komeda T, et al. Amplification and overexpression of cyclin D1 gene in aggressive human hepatocellular carcinoma. Cancer Res 1994; 54: 3107-10.
34. Choi Y L, Park S H, Jang J J, Park C K. Expression of the G1-S modulators in hepatitis B virus-related hepatocellular carcinoma and dysplastic nodule: association of cyclin D1 and p53 proteins with the progression of hepatocellular carcinoma. J Korean Med Sci 2001; 16: 424-32.
35. Jung Y J, Lee K H, Choi DW, et al. Reciprocal expressions of cyclin E and Cyclin D1 in hepatocellular carcinoma. Cancer Lett 2001; 168: 57-63.
36. Masaki T, Shiratori Y, Rengifo W, et al. Cyclins and cyclin-dependent kinases: comparative study of hepatocellular carcinoma versus cirrhosis. Hepatology 2003; 37: 534-43.
37. Cardoret A, Ovejero C, Saadi-Kheddouci S, et al. Hepatomegaly in transgenic mice expressing an oncogenic form of beta-catenin. Cancer Res 2001; 61: 3245-9.
38. Harada N, Miyoshi H, Murai N, et al. Lack of tumorigenesis in the mouse liver after adenovirus-mediated expression of a dominant stable mutant of beta-catenin. Cancer Res 2002; 62: 1971-7.
39. Harada N, Oshima H, Katoh M, et al. Hepatocarcinogenesis in mice with beta-catenin and Ha-Ras gene mutations. Cancer Res 2004; 64: 48-54.
40. Inagawa S, Itabashi M, Adachi S, et al. Expression and prognostic role of beta-catenin in hepatocellular carcinoma: correlation with tumor progression and postoperative survival. Clin Cancer Res 2002; 8: 450-6.
41. Catagay T, Ozturk M. p53 mutation as a source of aberrant β-catenin accumulation in cancer cells. Oncogene 2002; 21: 7971-80.
42. Zhao D H, Hong J J, Guo S Y, et al. Aberrant expression and function of TCF4 in the proliferation of hepatocellular carcinoma cell line BEL-7402. Cell Res 2004; 14: 74-80.